Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
Phase 3positivezenkudaPositive
AI Analysis
Summary
Kodiak Sciences' Phase 3 trial showed two assets matched Eylea performance, prompting regulatory submission of the anti-VEGF antibody zenkuda. The positive results drove stock up 166%.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Two assets matched Eylea in Phase 3 trial
Importance:8/10
Sentiment:
0.85
Phase_3_DataStock_SoarsAnti-VEGFRegulatory_Path
Related Companies
Read the original article
Published by BioSpace on September 28, 2026 3:11 PM